GLI1 and skin basal cell carcinoma: We also observed elevated levels of phosphorylated JNK in active nMRTF BCCs in comparison to inactive cMRTF BCC (Supplementary Fig. 3g, h), and treatment of resistant BCC cells with inhibitors of JNK (SP60012536 and JNK-IN-837) reduce Gli1 expression and cell viability (Supplementary Fig. 3d).